Sigilon Therapeutics

Sigilon Therapeutics

Sigilon Therapeutics

Immune-privileged living therapeutics
Type
B2c
Raised
$80.3M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$80,300,000
Venture capital (Series B) - 2020
Eli Lilly and Company Flagship Pioneering Canada Pension Plan Investment Board (CPP Investments) +1
Undisclosed amount
Undisclosed funding - 2018
Eli Lilly and Company
Team Size
1–10
Employees
$80,300,000 Venture capital (Series B)
FinSMEs

Sigilon Therapeutics Raises $80.3M in Series B Financing

Undisclosed funding
FinSMEs

Sigilon Therapeutics Receives Investment from Eli Lilly and Company

Health Funding Software development